Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...

Overall, Edwards enjoys a great deal of financial flexibility that would allow for more substantial acquisitions, if those opportunities were to arise. Edwards Lifesciences has come to dominate ...

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

The latest conference call transcript from Edwards Lifesciences Corporation has revealed a remarkable fourth quarter ...

Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...

Investors remain bullish on medical device makers, expecting them to benefit from still-high demand for surgical procedures, ...

Edwards Lifesciences had a higher profit and sales in its fourth quarter as demand for its products held strong. The medical-technology company posted a profit of $385.6 million, or 65 cents a share, ...

With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

David Correa Allied Market Research + + 1 800-792-5285 email us here Visit us on social media: Facebook X LinkedIn YouTube ...

NewsVoir New Delhi [India] 3 Indraprastha Apollo Hospitals proudly announces the launch of its Heart Valve Clinic a dedicated ...